Abstract
As a subtype of lymphocyte, natural killer (NK) cell is the first line of defense that shows a strong function in tumor immunotherapy response and clinical outcomes. The current study aims to investigate the prognostic influence of peripheral blood absolute NK cell count after four cycles of rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) treatment (NKCC4) in diffuse large B cell lymphoma (DLBCL) patients. A total of 261 DLBCL patients treated with R-CHOP from January 2018 to September 2022 were enrolled. The low NKCC4 was observed in patients who died during the study period compared with survival individuals. A NKCC4 < 135 cells/μl had a remarkable negative influence in overall survival and progression-free survival (PFS) compared to a NKCC4 ≥ 135 cells/μl (p < 0.0001 and p < 0.0004, respectively). In addition, the OS and PFS were synergistically lower in a NKCC4 < 135 cells/μl group among DLBCL patients with GCB type or high IPI. In conclusion, this study indicates NCKK4 as a valuable marker in clinical practice and provides an insight for combination treatment of R-CHOP to improve outcomes of DLBCL patients.
Introduction
Diffuse Large B-cell Lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma. While the standard R-CHOP regimen has significantly improved survival rates, nearly half of all patients still face relapse or treatment resistance. Currently, clinicians rely on the International Prognostic Index (IPI) to predict outcomes, but there is a growing need for dynamic biomarkers that reflect a patient's immune response during treatment. Natural Killer (NK) cells are the "first responders" of the innate immune system and are essential for the efficacy of rituximab through antibody-dependent cellular cytotoxicity (ADCC). This study investigates whether the absolute NK cell count measured midway through treatment (after four cycles, or NKCC4) can serve as a critical prognostic link.
Methods
The researchers conducted a retrospective study of 261 de novo DLBCL patients treated at Xiangtan Central Hospital between 2018 and 2022. The primary metric was NKCC4: the absolute NK cell count ($CD3^-CD56^+CD16^+$) in peripheral blood after four cycles of R-CHOP, measured via flow cytometry. To determine the optimal prognostic threshold, Receiver Operating Characteristic (ROC) curves were utilized to identify the cutoff value that best separated survivors from non-survivors.
Survival analysis was subsequently performed using Kaplan-Meier curves and log-rank tests to compare groups stratified by this cutoff.
Key Results
The study identified 135 cells/μl as the critical threshold for NKCC4.
- Survival Outcomes: Patients with a high NKCC4 (≥ 135 cells/μl) had significantly better outcomes. Low NKCC4 was strongly associated with decreased overall survival (OS, p < 0.0001) and progression-free survival (PFS, p < 0.0004).
- Subtype Sensitivity: The prognostic value of NKCC4 was particularly robust in the Germinal Center B-cell (GCB) subtype.
- Synergistic Risk: Low NKCC4 combined with a high IPI score identified an extremely high-risk group, suggesting that NKCC4 adds significant value to traditional risk stratification.
Additionally, while NKCC4 correlated with total lymphocyte counts ($R = 0.48$), it proved to be a more specific prognostic tool for predicting treatment failure than total lymphocyte counts alone.
Conclusion
This study highlights NKCC4 as a valuable dynamic marker in clinical practice. A low NK cell count mid-treatment likely reflects a lack of "ammunition" for rituximab-mediated cancer cell destruction. While limited by its retrospective nature and single-center design, these findings suggest that monitoring NKCC4 could help identify high-risk patients early, potentially guiding the use of NK-cell-based therapies or other treatment intensifications to improve outcomes in DLBCL.
Summary updated